Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Nurses screen patients for COVID-19 virus testing at a drive-up location outside Medstar St. Mary's Hospital on March 17, 2020 in Leonardtown, Maryland. Photo: Win McNamee/Getty Images

Pharma company Bayer will soon make a large donation to the U.S. government of a drug that has shown some promise in helping patients suffering from the novel coronavirus, according to a senior Health and Human Services official and another source with direct knowledge.

Why it matters: It doesn't hurt to have a potential treatment on hand, but we're still a very long way from having an approved, clinically tested treatment for the coronavirus.

The big picture: Early evidence suggests that chloroquine — an inexpensive anti-malarial drug — may work just as well, if not even better, than remdesivir, a drug owned by Gilead, which is undergoing clinical trials for treatment of the coronavirus.

  • A study published in Nature found that "remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro."
  • "Chloroquine shouldn’t be left out of the discussion of candidate COVID-19 therapies and may actually be leading the pack," Raymond James wrote in a research note earlier this month.

Yes, but: This doesn't change the need for massive coronavirus efforts, as there is no proven coronavirus treatment or vaccine.

Go deeper

Biden pollster urges blunt tax talk

Illustration: Aïda Amer/Axios

The top pollster for Joe Biden's presidential campaign is advising the White House to do something that often makes Democrats nervous: Talk loudly and proudly about raising taxes on the rich.

Why it matters: John Anzalone tells Axios his extensive polling and research has found that few issues receive broader support than raising taxes on corporations and people earning more than $400,000 a year.

On the front lines of the growing border crisis

A migrant mother and her children sit in the dirt at a temporary processing center under the Anzalduas International Bridge in McAllen, Texas. Photo: Stef Kight/Axios

At night, parents with young children march through the brush after crossing the Rio Grande River in the pitch black. By day, unaccompanied kids arrive at shelters, in one instance 17 of 17 testing positive for COVID-19.

Driving the news: Axios accompanied a delegation of Republican lawmakers to South Texas last week — followed by a unilateral visit to El Paso — to see in real-time the challenges fueled by a border surge, the effects of actions taken by the previous administration, and the lagging response by the new one.

Scoop: Trump campaign boosted by unsuspecting state GOPs

Illustration: Sarah Grillo/Axios

Federal regulators are probing financial reporting discrepancies stemming from an effort to funnel $75 million through state Republican parties to the national GOP effort to reelect Donald Trump, Axios has learned.

Why it matters: In comments to Axios and filings with the Federal Election Commission, some state party officials seemed unaware of their roles.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!